<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378649</url>
  </required_header>
  <id_info>
    <org_study_id>1839-14-SMC</org_study_id>
    <nct_id>NCT02378649</nct_id>
  </id_info>
  <brief_title>PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension</brief_title>
  <official_title>A Randomized, Placebo Controlled, Single Center Clinical Trial for Evaluation of Efficacy and Safety of Sildenafil Administration in the Cardiac ICU Following Mitral Valve Surgery in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Robert Klempfner Heart Rehabilitation Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      A randomized, placebo controlled, single center clinical trial for evaluation of efficacy and
      safety of Sildenafil administration in the cardiac ICU following Mitral Valve (MV) Surgery in
      patients with pre-operative Significant Pulmonary Hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate if sildenafil results in greater reduction in average mean pulmonary artery pressure (mPAP) compared to placebo. (Percent change in mPAP pressure at 48 hours as compared to the immediate post operative averages.)</measure>
    <time_frame>48 hours</time_frame>
    <description>Percent change in mPAP pressure at 48 hours as compared to the immediate post operative averages. Pulmonary pressures will be obtained through invasive hemodynamic measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total surgical intensive care time</measure>
    <time_frame>participants will be followed for the duration of ICU stay, an expected average of 4 days</time_frame>
    <description>Duration of Surgical ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity post operation (Change in NYHA functional class (optional 6MWT pre-discharge)</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <description>Change in NYHA functional class (optional 6 minute walk test [6MWT] pre-discharge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study treatment related serious adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 days</time_frame>
    <description>Absence of serious adverse events related to study drug (shock, organ hypoperfusion, significant arrythmia and any other major event as defined by GCP guidelines) during hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Mitral Valve Surgery</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.
PDEI or placebo will continue up to 8 days or discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.
PDEI or placebo will continue up to 8 days or discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio \ Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator concomitant with best practice usual care</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 22

          2. Undergoing mitral valve surgery (either repair or replacement) with or without
             coronary revascularization, aortic valve replacement (AVR) or repair; or tricuspid
             valve surgery.

          3. Pre-operative pulmonary arterial systolic pressure &gt;50 mm Hg as determined by resting
             echocardiography and post-operative sPAP &gt; 45 mmHg as obtained from invasive
             hemodynamics measurements.

          4. Willing and able to give written informed consent prior to the procedure

        Exclusion Criteria:

          1. Hypersensitivity to study drug

          2. Women of child-bearing potential

          3. Expected need to administer nitrates that are clinically indicated peri-operatively

          4. Post-operative hypotension (systolic blood pressure (BP) &lt;80) or evidence of shock
             (postoperative evidence of any kinds of shock)

          5. Cardiac or systemic amyloidosis

          6. Active malignancy other than BCC (basal cell carcinoma)

          7. Stable kidney dysfunction with Creatine clearence (CrCl) &lt;30 mL/min during the
             screening period or hepatic failure other than mild

          8. Significant anemia (hemoglobin &lt;8 mg/dl) preoperative.

          9. Known drug or alcohol dependence or any other factors which will interfere with the
             study conduct or interpretation of the results or in the opinion of the investigator
             are not suitable to participate;

         10. Any illness other than cardiac which might reduce life expectancy to less than 1 year
             from screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ido Ferstenfeld, MD</last_name>
    <email>Ido.Ferstenfeld@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiac Surgical Department, Leviev Heart Center</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel Hashomer</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ido Ferstenfeld, M.D</last_name>
      <email>Ido.Ferstenfeld@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>October 23, 2016</last_update_submitted>
  <last_update_submitted_qc>October 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Robert Klempfner Heart Rehabilitation Institute</investigator_full_name>
    <investigator_title>Dr. Ferstenfeld Ido</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

